505,999 Shares in Henry Schein, Inc. $HSIC Purchased by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon acquired 505,999 shares of Henry Schein worth approximately $42.3 million, representing about 0.44% of the company. Institutional investors collectively own 96.62% of HSIC.
• Henry Schein exceeded quarterly expectations, reporting $1.27 in earnings per share and $3.46 billion in revenue, with revenue up 6.7% year over year. The company maintained fiscal 2026 EPS guidance of $5.29–$5.39.
• Analysts maintain a Moderate Buy consensus, with an average price target of $92.93; targets range from $82 to $110, while HSIC recently opened at $90.28.

Bank of New York Mellon Corp purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 505,999 shares of the company's stock, valued at approximately $42,261,000. Bank of New York Mellon Corp owned approximately 0.44% of Henry Schein as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Parallel Advisors LLC raised its stake in shares of Henry Schein by 12.7% in the first quarter. Parallel Advisors LLC now owns 1,314 shares of the company's stock valued at $97,000 after purchasing an additional 148 shares in the last quarter. Jain Global LLC increased its holdings in Henry Schein by 2.0% in the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company's stock valued at $708,000 after buying an additional 207 shares during the period. Sanctuary Advisors LLC increased its holdings in Henry Schein by 4.5% in the 4th quarter. Sanctuary Advisors LLC now owns 4,856 shares of the company's stock valued at $367,000 after buying an additional 209 shares during the period. Captrust Financial Advisors raised its stake in shares of Henry Schein by 3.6% in the 4th quarter. Captrust Financial Advisors now owns 6,105 shares of the company's stock valued at $461,000 after buying an additional 210 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Henry Schein by 1.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company's stock valued at $1,155,000 after buying an additional 229 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company's stock.

Henry Schein Price Performance

NASDAQ:HSIC opened at $90.28 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. The firm has a market cap of $10.06 billion, a PE ratio of 26.32, a price-to-earnings-growth ratio of 1.72 and a beta of 0.80. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $92.18. The company's 50-day moving average price is $86.49 and its two-hundred day moving average price is $79.93.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.03. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The company had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same quarter last year, the business posted $1.10 earnings per share. The company's revenue was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, equities analysts anticipate that Henry Schein, Inc. will post 5.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HSIC. Stifel Nicolaus set a $95.00 price objective on shares of Henry Schein in a report on Wednesday, August 5th. Robert W. Baird set a $97.00 price target on shares of Henry Schein in a research report on Wednesday, May 6th. Mizuho cut their price target on shares of Henry Schein from $88.00 to $82.00 and set a "neutral" rating for the company in a research note on Wednesday, May 6th. Piper Sandler lifted their price objective on Henry Schein from $91.00 to $95.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Finally, BTIG Research upped their price objective on Henry Schein from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, August 19th. Nine equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $92.93.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source